Immunome Inc. (NASDAQ:IMNM) reported that Chief Financial Officer Rosett Max sold 65,000 shares of company common stock on April 2, 2026, generating about $1.4 million in proceeds. The sales were transacted at prices between $21.91 and $22.48 per share.
In conjunction with the share disposals, the filings indicate that Rosett Max exercised stock options to purchase a total of 71,561 shares of Immunome common stock. Those options carried exercise prices of $1.05 and $1.35, and the resulting acquisition of shares is recorded as worth $87,052.
After the combination of option exercises and open-market sales, Rosett Max now directly holds 54,037 shares of Immunome Inc.
The insider transactions were carried out under a pre-arranged Rule 10b5-1 trading plan that was adopted on December 26, 2025.
At the time of the disclosed activity, IMNM shares were trading near $21.84. Over the trailing 12 months the stock has delivered a 250% total return.
Market commentary included in the filings notes that InvestingPro analysis views the stock as slightly undervalued at current levels. Analysts polled by the service continue to hold bullish price targets on IMNM, with a range spanning $30 to $40.
The company’s balance sheet position is highlighted as having more cash than debt. However, InvestingPro Tips cited in the filings also emphasize that the stock’s price movements remain quite volatile, and that five analysts have recently revised earnings estimates upward.
Separately, H.C. Wainwright has initiated coverage on Immunome Inc. with a Buy rating and set a $40.00 price target. In its initiation note, the firm pointed to Immunome’s developing portfolio of oncology assets that the bank believes show differentiation across solid tumor and hematologic indications. H.C. Wainwright specifically identified Immunome’s lead asset, varegacestat, as a potentially superior gamma-secretase inhibitor for desmoid tumors relative to the currently approved therapy, Ogsiveo, according to the coverage initiation.
Context and market signals
The filings combine an executive's exercise of long-held, low-priced options with a contemporaneous sale of market-priced shares under a predetermined trading plan. The company-level notes included with the disclosures emphasize recent performance metrics, valuation viewpoints from InvestingPro, and new analyst coverage from H.C. Wainwright.
Where the public record provides limited additional detail, the filings document the mechanics and immediate outcomes of the transactions, the trading plan under which they were executed, and the analyst perspectives and balance sheet characterization reported alongside the insider activity.